LASA Supergenerics Files SDD Compliance Certificate for Q4 FY26
Lasa Supergenerics Limited filed its SDD Compliance Certificate for the quarter ended March 31, 2026. The company confirmed adherence to SEBI (Prohibition of Insider Trading) Regulations, 2015, with a functional and secure Structured Digital Database.
This is a standard regulatory filing and is not expected to have any significant impact on the company's stock price or business operations.
The announcement is a routine compliance filing and does not contain any material information that would positively or negatively impact the company's stock.
Lasa Supergenerics Limited has submitted its Structural Digital Database (SDD) Compliance Certificate for the quarter ended March 31, 2026. The certificate, submitted to the BSE and NSE, confirms the company's adherence to SEBI (Prohibition of Insider Trading) Regulations, 2015.
The Compliance Officer, Mitti Jain, certified that the company has a functional SDD system in place. Key aspects confirmed include controlled access to the database, proper capture of Unpublished Price Sensitive Information (UPSI) with dates and times, internal maintenance with audit trails, and a non-tamperable system capable of retaining records for eight years.
The company also confirmed that it captured the required two events during the quarter and the fiscal year. No non-compliance was reported for the previous quarter, and no remedial actions were necessary.
What to do with a filing like this
Lasa Supergenerics Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lasa Supergenerics Limited. Read the original for the full detail.